CompuGroup Medical AG

Financial Report
1 January - 31 March 2012



Synchronizing Healthcare

CompuGroup Medical

Contents:

Key Events and Figures

- + Broad-based positive start to 2012
- + First quarter revenue of EUR 112.2 million, an increase of 24 percent compared to the same period of 2011
- + Organic growth of 6 percent
- + Operating profit (EBITDA) of EUR 26.3 million, up from EUR 14.0 million in the first quarter of 2011
- + Operating margin of 23 percent, up from 15 percent
- + Operating cash flow of EUR 54.7 million, up from EUR 33.6 million last year
- + Cash net income of EUR 14.7 million and cash net income per share of EUR 0.29
- + Continued improvement in the US business
- + Market position strengthened in the Netherlands and Italy
- + 2012 guidance reaffirmed

EUR ´000	01.01-31.03 2012	01.01-31.03 2011	Change
Revenue	112,244	90,272	24%
EBITDA	26,312	13,974	88%
margin in %	*23*	*15*	
EBITA	24,416	12,493	95%
margin in %	*22*	*14*	
EPS (EUR)	0.16	0.02	
Cash net income (EUR)*	14,704	8,069	
Cash net income per share (EUR)	0.29	0.16	83%
Cash flow from operating activities	54,677	33,641	
Cash flow from investing activities	-26,144	-24,738	
of which equity acquisitions	-14,306	-20,062	
Number of shares outstanding (‘000)	49,934	50,229	
Net debt	218,132	165,645	

* Cash net income: net income before minority interests plus amortization on intangible assets except amortization on in-house capitalized software.

Management report

FINANCIAL REVIEW

Unless stated otherwise, all figures in the management report refer to the first quarter of 2012 and 2011 respectively, i.e. the three month period 01.01 – 31.03 (Q1).

Revenue

Revenue in the first quarter of 2012 was EUR 112.2 million compared to EUR 90.3 million in the same period last year. This represents an increase of 24 percent. Acquisitions give a growth contribution of 18 percent and organic growth was 6 percent.

In the HPS segments, revenue was EUR 94.4 million compared to EUR 73.8 million in the first quarter of 2011. This represents an increase of 28 percent of which 6 percent is organic growth.

Ambulatory Information Systems (AIS) grew 11 percent of which 6 percent is organic growth. The organic growth in AIS primarily stems from new value-added products and services sold to existing customers. Total revenue in the first quarter of 2012 from the US was EUR 11.4 million (USD 15.0 million), up from EUR 10.6 million (USD 14.5 million) in the same period in 2011.

Within Hospital Information Systems (HIS) the year-on-year growth was 7 percent going from the first quarter of 2011 to the first quarter of 2012, all of which is organic growth. It has been a good start to the year for the hospital business in Poland, Switzerland and in the Middle-East and these markets drive the first quarter 2012 HIS revenue growth.

Pharmacy Information Systems (PCS) is a new sub-segment within HPS following the Lauer-Fischer acquisition in June 2011. First quarter 2012 PCS revenue was EUR 13.2 million which is 3 percent higher than the unconsolidated revenue in the same period of 2011.

HPS revenue development (including acquisitions and exchange rate effects):

EUR m	01.01-31.03 2012	01.01-31.03 2011	Change
Ambulatory Information Systems	62.4	56.2	11%
Hospital Information Systems	18.8	17.6	7%
Pharmacy Information Systems	13.2	0.0	
SUM	94.4	73.8	28%

Growth from acquisitions in HPS resulted from the first-time consolidated revenue of the following entities:

EUR m	First-time revenue	Sub-segment
Lauer Fischer	13.2	PCS
Microbais	2.8	AIS
Effepieffe	0.3	AIS
SUM	16.3	

In the HCS segment, revenue was EUR 17.6 million compared to EUR 16.3 million in the first quarter of 2011. This represents an increase of 8 percent, all of which is organic growth. Revenue in Communication & Data grew 14 percent, from EUR 7.4 million in the first quarter of 2011 to EUR 8.5 million in the first quarter of 2012. The strong start to the year in Communication & Data is driven by a high number of drugs coming off patent which drives additional products and services for generics producers during this particular quarter.

The business volume in Workflow & Decision Support grew 4 percent, from EUR 6.4 million in the first quarter 2011 to EUR 6.7 million in the first quarter this year. Sales of products and services to health insurance companies in Germany continue at a slow pace. The year-on-year growth in Internet Service Provider revenue stems from new subscribers of Internet connections and sales of associated data security products and services.

HCS revenue development:

EUR m	01.01-31.03 2012	01.01-31.03 2011	Change
Communication & Data	8.5	7.4	14%
Workflow & Decision Support	6.7	6.4	4%
Internet Service Provider	2.5	2.5	1%
SUM	17.6	16.3	8%

Changes to currency exchange rates increased revenue insignificantly by EUR 0.3 million (0.3 percent) going from the first quarter of 2011 to the first quarter of 2012.

Profit

Consolidated EBITDA amounted to EUR 26.3 million compared to EUR 14.0 million in the first quarter of 2011. The corresponding operating margin was 23 percent compared to 15 percent last year. The strong margin development is driven by successful integration and efficiency improvements in companies acquired during the last 18 months. The most pronounced effect comes from the turnaround of the US business which had EBITDA of EUR 1.2 million during the first quarter of 2012 (11 percent margin) compared to EUR – 1.5 million in the same period in 2011 (-15 percent margin).

+ The gross margin for the first quarter of 2012 is 83 percent which is comparable to the same period in 2011 (82 percent). The stable gross margin is explained by only small changes to the HPS revenue mix going from the first quarter of 2011 to 2012, with the new pharmacy business (Lauer-Fischer) having a very similar gross margin. The HCS segment has only minor expenses for goods and services purchased.

+ Personnel expenses increased from EUR 46.1 million in the first quarter 2011 to EUR 54.2 million in the same period this year. This increase is attributable to new employees in companies acquired during the last 12 months.

+ Other expenses decreased from EUR 15.7 million in the first quarter 2011 to EUR 15.2 million in 2012. This decrease comes despite the added cost base in new companies acquired and is driven by efficiency improvements particularly in marketing and travel costs as well as from lower spending on consultants and advisors related to acquisitions.

Depreciation of tangible fixed assets was EUR 1.9 million in the first quarter of 2012, up from EUR 1.5 million in the first quarter of 2011. This increase comes from normal fixed assets depreciation in new companies acquired. Amortization of intangible fixed assets went down from EUR 7.9 million in the first quarter of 2011 to EUR 7.5 million in the first quarter of 2012. The decrease is caused by adjustments to purchase price allocations and by intangible assets which by now have been fully amortized, balanced by amortization of intangible assets from new companies acquired. There may still come smaller adjustments to the quarterly amortization figure based on the finalization of the purchase price allocation of the Lauer-Fischer, Microbais and Effipieffe acquisitions. Also, the amortization of self-developed software may be adjusted from time to time to reflect changes to the useful life of assets.

Financial income was EUR 0.4 million in the first quarter of 2012 which is lower than the same period last year due to a lower cash balance held in 2012. The financial expense of EUR 6.4 million during the first quarter of 2012 is composed of the following items:

EUR m	01.01-31.03 2012	01.01-31.03 2011
Interest and expenses on EUR 330 million syndicated loan facility	2.3	1.4
Interest and expenses on other bank loans	1.4	1.6
Interest for purchase liabilities	0.8	0.6
Fair value evaluation of interest SWAP	0.3	-0.8
Translation loss on non-Euro internal debt	1.6	0.8
SUM	6.4	3.6

After tax earnings came in at EUR 8.1 million in the first quarter of 2012, compared to EUR 1.0 million in the first quarter of 2011. The tax rate was 27 percent in the first quarter this year compared to 41 percent in the first quarter of 2011. The different tax rates are mostly due to non-cash changes in deferred tax assets and liabilities.

Cash net income increased from EUR 8.1 million in the first quarter 2011 to EUR 14.7 million in the first quarter 2012, corresponding to a Cash net income per share of 29 Cent (Q1/2011: 16 Cent).

Cash flow

Cash flow from operating activities during the first quarter of 2012 was EUR 54.7 million compared to EUR 33.6 million in the first quarter of 2011. The increase in operating cash flow is mostly due to higher net profit and higher volume of pre-paid customer contracts balanced under other non-financial liabilities.

Cash flow from investment activities during the first quarter of 2012 amounted to EUR -26.1 million compared to EUR -24.7 million in the same period last year. During the first quarter of 2012, CGM's capital expenditure consisted of the following:

EUR m	01.01-31.03 2012
Acquisition of Microbais and Effepieffe	14.3
Capitalized in-house services and other intangible assets	2.1
Office buildings and property	8.6
Other property and equipment	1.1
SUM	26.1

Investments in office buildings and property arise from the continued construction of the new administration building at the company headquarter in Koblenz (EUR 2.5 million). The new building was completed and inaugurated in April 2012. Also, the building 'Maria Trost 21' in Koblenz, which has been rented and used by CompuGroup for more than 10 years, was purchased during the quarter for EUR 6.1 million. The owner of the building was Mr. Frank Gotthardt and the purchase price was based on an independent valuation report and a unanimous approval by the Supervisory Board. The 'campus Koblenz' technology park now consists of 12 buildings with more than 20,000m² of office space – all fully owned by CompuGroup.

Cash flow from financing amounted to EUR -7.8 million during the first quarter of 2012 and was primarily incurred through repayment of loans and adjustments to credit facilities. The office building 'Maria Trost 21' was financed during the quarter with a 10 year secured real-estate mortgage loan with a fixed interest rate of 3.3 percent.

Balance sheet

Since the balance sheet of 31 December 2011, total assets increased by EUR 46.4 million to EUR 687.1 million as at 31 March 2012. The largest change to individual asset classes is a EUR 20.7 million increase in cash and cash equivalents. Intangible assets increased EUR 8.8 million due to company acquisitions (less amortization) and land and buildings increased EUR 6.4 million due to the construction and purchase of office buildings in Koblenz (less depreciation). Trade receivables increased with EUR 6.0 million. For all other assets there are only minor changes during the first quarter of 2012.

Group equity was EUR 174.8 million as at 31 March 2012, up from EUR 168.2 million as at 31 December 2011. The increase in equity comes primarily from the addition of net income for the period. The equity ratio has gone from 26 percent at the end of 2011 to 25 percent at the end of the first quarter of 2012.

Under liabilities, the changes from 31 December 2011 are mostly related classification of short/long term debt and an increase in pre-payments of software maintenance contracts balanced under other liabilities (EUR 47.8 million change).

Research and Development

Under IAS 38, development work on internally generated software must be capitalized if certain criteria are fulfilled. This generated EUR 1.5 million additional operating profit for the Group during the first quarter of 2012 (previous year EUR 1.7 million), less amortization and write-downs of EUR 0.8 million during the same period (previous year EUR 0.7 million). Most of the capitalized software development expenses are accounted for by two projects, G3.HIS (new HIS system development) and G3.AIS (new AIS software generation). Upon completion, the software will be amortized based on its useful life.

OPERATIONAL REVIEW

CompuGroup Medical is currently represented with offices and employees in 19 countries. According to internal figures, CompuGroup Medical has software maintenance contracts in the HPS segment corresponding to approximately 250,000 healthcare professionals (doctors, dentists and pharmacists). Total reach across all segments is estimated at approximately 385,000 healthcare professionals.

The Group had an average of 3,512 employees during the first quarter of 2012 (previous year: 3,228). As at 31 March 2012, the total number of employees in group companies was 3,518. Personnel expenses during the first quarter of 2012 was EUR 54.2 million (previous year: EUR 46.1 million) and consists mainly of salaries, social security contributions and related expenses. In addition, variable performance-based pay may be granted to senior executives and sales staff.

The following sections describe the main operational developments during the first quarter of 2012.

Acquisition of Microbais Werkmaatschappij B.V., Netherlands

In January 2012, CompuGroup Medical AG concluded an agreement for the acquisition of all shares in Microbais Werkmaatschappij B.V. Microbais is one of the leaders in the Dutch market for ambulatory and pharmacy information systems. Revenue in 2011 was approximately EUR 11.2 million and EBITDA approximately EUR 2.5 million. The purchase price for 100 percent of the shares was EUR 15.0 million and was financed from cash and cash equivalents and existing credit lines. Microbais has around 90 employees and headquarters in Amsterdam. The company's customer base includes approximately 475 pharmacies and 150 physicians' offices. This corresponds to a market share of around 25 percent for pharmacies and 4 percent for physicians in private practice in the Netherlands.

This acquisition expands CompuGroup Medical's market share in the Netherlands to around 45 percent of pharmacies and 15 percent of ambulatory information systems. CompuGroup Medical aims to provide customers with access to its international product platform so they can benefit from the numerous intelligent software assisted medicine (SAM) solutions that are global leaders in terms of innovation and security. As part of the transaction, CompuGroup Medical also receives a 51 percent majority share in MediPharma Online, a startup company in the field of networking between patients and pharmacies.

Acqusition of Effepieffe srl., Italy

In January 2012, CompuGroup Medical AG signed a purchase agreement for the acquisition of all shares in Effepieffe srl. via its subsidiary CompuGroup Medical Italia S.p.A. Effepieffe's revenue in 2011 came to around EUR 1.2 million and EBITDA to approximately EUR 0.5 million. The purchase price for 100 percent of the shares amounts to EUR 3.4 million and a variable component amounting to maximum EUR 1.0 million. The company counts approximately 8,000 general practitioners among its customers and is the third-largest ambulatory information system provider in Italy. This latest acquisition is another step toward continuously expanding CompuGroup Medical's position in the Italian market. Since its market entry in 2006, the company is consistently pursuing a growth strategy and today is the market leader in Italy in the field of primary care with a share of around 40 percent. Effepieffe's strategy focuses on the North Italian market. A majority of its customers are based in the area around the company headquarters in Milan.

CompuGroup Medical Expands the Technology Park in Koblenz

In April 2012, CompuGroup Medical inaugurated the new corporate headquarters in Koblenz. The 300 guests included selected customers, business partners, employees and political dignitaries such as the governor of Rheinland-Pfalz Kurt Beck (SPD), Julia Klöckner (CDU), Dr. Michael Fuchs (Member of the German Bundestag and Deputy Chairman of the CDU/CSU Bundestag Faction) and Professor Dr. Joachim Hofmann-Göttig (SPD). After only 19 months of construction, the new corporate headquarters was completed in the CGM technology park in Koblenz, including executive offices, an innovation forum and an office building. The expansion on the grounds of the historical Maria Trost site starts another chapter in CGM's 25-year history of growth.

International expansion of CGM LIFE eSERVICES

CompuGroup Medical was one of the first companies to develop a fully integrated online service for medical offices – the CGM LIFE eSERVICES. Services like online appointment scheduling, online prescriptions, online findings inquiries and online consultations can be taken care of via the medical office website which is fully compatible with the ambulatory information system that the doctors already use. The online services not only represent an innovative additional service for patients, they also lower administrative expenditures and efforts and cut down on phone calls for the physician practice. After a successful piloting phase in Germany and Austria, the CGM LIFE eSERVICES will now be rolled out internationally. The services are currently being tailored to the needs of individual markets and the legal framework in regional piloting phases. From mid of this year they will be introduced in France, Italy, Belgium, the Czech Republic and the USA.

United States and status for CompuGroup

As expected and previously announced, the 5010 'industry meltdown' significantly influenced the business in the United States during the first quarter of 2012. However, despite this challenge, CompuGroup's US business delivered its strongest quarter ever with year-on-year organic growth and 11 percent EBITDA margin.

As of April 2012, the issues related to 5010 are mostly resolved and the business is back normal operating conditions. This will gradually free up internal capacity in CompuGroup which can now be redirected to sales and implementation activities. Potential customers will also be able to devote more attention to new developments and in particular EHR adoption instead of dealing with 5010 problems.

The market feedback on EHR adoption in small practices (<10 doctors) continues to be that doctors want an effective and easy to use EHR and that EHR adoption will greatly increase in the US in the coming years – with or without Meaningful Use and incentive payments. The key success factors in the US market are identical to Europe: Reliable and effective products backed by excellent service and customer support. CGM has what it takes to succeed and expects the US business to gradually improve and grow in the following quarters of 2012.

Development of Communication & Data business

The Communication & Data business had a particularly strong first quarter of 2012 which was due to especially favorable short-term market conditions. Several big drugs came off patent during this quarter and this drove extra demand from generics producers to introduce new products to the market. The general trend however, is that C&D revenue continues to decline from the generics part of the market as rebate contracts 'without choice' become more and more the norm for German health insurance companies. For the second quarter of 2012, CompuGroup Medical expects Communicatoin & Data revenue to be approximately one million Euro lower than realized in the first quarter.

REPORT ON OPPORTUNITIES AND RISKS

As an internationally operating company, CompuGroup Medical is subject to variety of different risks. These risks mainly include strategic and macroeconomic risks as well as operating, legal and political risks. Furthermore, the group is faced with risks resulting from its project-business, risks related to key personnel and financial risks.

The group's technological expertise and market knowledge makes it possible to assess risk and apply appropriate measures to actively manage the risk exposure. To guarantee a responsible risk handling, CompuGroup works with standardized, group-wide integrated risk management system so that risks can be identified and analyzed at an early stage. A detailed description of the main risks and the specific structure of the risk management system can be found in the CompuGroup Medical AG annual report of 2011. It can be downloaded free of charge from the company's website www.cgm.com.

There were no substantial changes in risk positions during the first three months of 2012 in comparison to the risks presented in the CompuGroup Medical AG Annual Report 2011. Risks that may impact the company as a going concern were not evident during the first three months of 2012, neither in form of individual risks nor from total risk perspective for CompuGroup Medical as a whole.

OUTLOOK

CompuGroup Medical reaffirms the outlook presented in the 2011 Annual Report which was published on 29 March 2012.

In terms of total Group revenue, the growth rate is expected to be 11-15 percent in 2012, of which 3-6 percent is expected to be organic growth. For the consolidated Group, the EBITDA margin is expected to increase from 21 percent and 18 percent in 2010 and 2011 respectively to 22-23 percent in 2012. In summary, CompuGroup Medical offers the following guidance for 2012:

+ Revenue is expected to be in the range of EUR 440 million to EUR 460 million.
+ Operating income (EBITDA) is expected to be in the range of EUR 95 million to EUR 105 million.

Depreciation of fixed assets is on Group level expected to be approximately EUR 8 million in 2012 and amortization of intangible assets is expected to be approximately EUR 30 million, of which EUR 26 million will come from amortization of purchase price allocations related to past acquisitions. The corresponding Group earnings before interest and tax (EBIT) is in 2012 expected to be in the range of EUR 57 million to EUR 67 million.

The foregoing outlook is given as at May 2012 and does not include revenue and costs associated with potential and currently undetermined further acquisitions during 2012. The outlook for 2012 represents management's best estimate of the market conditions that will exist in 2012 and how the business segments of CompuGroup Medical will perform in this environment.

RELATED PARTY DISCLOSURES

Related Party Disclosures within the meaning of IAS 24 are outlined in the notes of the Annual Report as per 31 December 2011. In the reporting period, a major business transaction with associated companies and persons was:

With notarized purchase agreement dated 2 January 2012, CGM Deutschland AG acquired a property including an office building, which had been leased from Mr. Frank Gotthardt on a long-term basis. The Supervisory Board of the company approved the transaction in December 2011. The decision and the purchase price determination were based on an expert's market value appraisal dated 28 November 2011. The agreed purchase price was EUR 6.1 million.

Statement of Financial Position

as at 31 March 2012

ASSETS

	31.03.2012 EUR '000	31.03.2011 EUR '000	31.12.2011 EUR '000
Non-current assets			
Intangible assets	467,534	415,911	458,776
Tangible assets			
Land and buildings	32,730	24,733	26,358
Other facilities, plant and equipment	26,339	17,757	23,842
Financial assets			
Interests in affiliates (valued as equity)	982	1,010	971
Other Investments	106	293	105
Trade receivables	8,689	0	8,404
Other financial assets	10,265	10,107	9,726
Deferred taxes	5,121	5,963	5,851
	551,766	475,774	534,033
Current assets			
Inventories	4,339	1,461	3,666
Trade receivables	67,049	45,543	61,354
Other financial assets	6,711	4,868	6,730
Other non-financial assets	10,199	10,947	8,776
Income tax claims	2,090	3,311	1,698
Securities (recognized as profit or loss at fair value)	251	201	178
Cash and cash equivalents	44,672	95,534	23,979
	135,311	161,864	106,381
Non-current assets qualified as held for sale	0	3,182	300
	687,077	640,820	640,714

SHAREHOLDER EQUITY AND LIABILITIES

	31.03.2012 EUR '000	31.03.2011 EUR '000	31.12.2011 EUR '000
Shareholder Equity			
Subscribed capital	53,219	53,219	53,219
Treasury shares	-17,158	-14,384	-16,257
Reserves	138,704	140,509	131,169
Capital and reserves allocated to the shareholder of the parent company	174,765	179,344	168,131
Minority interests	71	334	71
	174,836	179,678	168,202
Long-term liabilities			
Pension provision	5,972	959	5,765
Liabilities to banks	240,376	226,373	233,996
Purchase price liabilities	16,284	6,517	16,150
Other financial liabilities	4,072	4,682	4,347
Other non-financial liabilities	1,817	1,810	1,840
Derivative financial instruments	8,144	0	6,290
Deferred taxes	52,223	60,087	51,838
	328,888	300,428	320,226
Current liabilities			
Liabilities to banks	22,428	34,806	35,746
Trade payables	17,720	14,429	21,182
Income tax liabilities	14,022	7,139	15,146
Provisions	22,770	20,232	22,685
Purchase price liabilities	23,141	18,085	22,512
Other financial liabilities	8,359	4,162	7,926
Other non-financial liabilities	74,913	60,411	27,089
Derivative financial instruments	0	487	0
	183,353	159,751	152,286
Liabilities associated directly with non-current assets qualified as held for sale	0	963	0
	687,077	640,820	640,714

Total Comprehensive Income Statement

for the reporting period of 1 January - 31 March 2012

	01.01-31.03 2012 EUR '000	01.01-31.03 2011 EUR '000	01.01-31.12 2011 EUR '000
Sales revenue	112,244	90,272	396,564
Capitalized in-house services	1,454	1,687	6,474
Other Income	807	428	3,937
Expenses for goods and services purchased	-18,825	-16,521	-74,392
Personnel costs	-54,202	-46,149	-190,608
Other expense	-15,166	-15,743	-68,910
Earnings before interest, taxes depr. and amortization (EBITDA)	26,312	13,974	73,065
Depreciation of property, plants and tangible assets	-1,896	-1,481	-6,317
Earnings before interest, taxes and amortization (EBITA)	24,416	12,493	66,748
Amortization of intangible assets	-7,447	-7,862	-30,093
Earnings before interest and taxes (EBIT)	16,969	4,631	36,655
Results from associates recognised at equity	11	0	22
Financial income	398	680	4,826
Financial expense	-6,370	-3,579	-16,305
Earnings before taxes (EBT)	11,008	1,732	25,198
Taxes on income for the period	-2,956	-707	-15,927
Consolidated net income for the period	8,052	1,025	9,271
of which: allocated to parent company	8,052	1,023	9,159
of which: allocated to minority interests	0	2	112
Other results			
Cash flow hedges			
of which: in equity	-1,854	0	-6,666
of which: income	0	0	376
Deferred taxes on cash flow hedges	550	0	1,865
Currency conversion differences	782	-4,088	-2,169
Total comprehensive imcome for the period	7,530	-3,063	2,677
of which: allocated to parent company	7,530	-3,065	2,565
of which: allocated to minority interests	0	2	112
Earnings per share			
undiluted (EUR)	0.16	0.02	0.18
diluted (EUR)	0.16	0.02	0.18
Cash net income (EUR)*	14,704	8,069	35,759
Cash net income per share (EUR)	0.29	0.16	0.72

* Cash net income: net income before minority interests plus amortization on intangible assets except amortization on in-house capitalized software.

Cash Flow Statement

as at 31 March 2012

	01.01-31.03 2012 EUR '000	01.01-31.03 2011 EUR '000	01.01-31.12 2011 EUR '000
Group net income	8,052	1,025	9,271
Amortization of intangible assets, plant and equipment	9,343	9,343	36,410
Earnings on sales of fixed assets	0	0	-1,855
Change in provisions (including income tax liabilities)	-917	-2,602	7,564
Change in deferred taxes	-1,712	-1,503	-4,527
Other non-cash earnings/expenditures	1,928	-1,068	-479
	16,693	5,195	46,384
Change in inventories	-471	-23	34
Change in trade receivables	-2,727	5,944	274
Change in other receivables	-611	-888	828
Change in income tax receivables	-384	1,289	3,832
Change in securities (valued at actual cash value)	-73	46	69
Change in trade accounts payables	-4,529	-1,662	831
Change in other short-term liabilities and derivative financial instruments	47,148	23,592	-5,026
Change on other long-term liabilities	-369	148	-490
Cash flow from operating activities	54,677	33,641	46,736
Cash inflow on disposals of sales of property, plant and equipment	546	102	643
Cash outflow for capital expenditure in property, plant and equipment	-10,287	-2,463	-12,368
Cash inflow on disposals of intangible assets	0	10	849
Cash outflow for capital expenditure in intangible assets	-2,097	-2,325	-10,513
Disposal of subsidiaries less cash transferred	0	0	486
Cash outflow for the acquisition of subsidiaries from prior periods	0	0	-5,831
Acquisition of companies less assumed cash and cash equivalents	-14,306	-20,062	-71,669
Cash flow from investing activities	-26,144	-24,738	-98,403
Purchase of own shares	-901	0	-1,873
Dividends paid	0	0	-12,557
Purchase of minority interest	0	0	-3,614
Cash inflow from assumption of loans	6,100	109,000	185,265
Cash outflow from the repayment of loans	-13,038	-64,549	-133,246
Cash flow from financing activities	-7,839	44,451	33,975
Changes in cash due to exchange rates	0	0	-510
Change in cash and cash equivalents	20,694	53,354	-17,692
Cash and cash equivalents at the beginning of the period	23,978	42,180	42,180
Cash and cash equivalents at the end of the period	44,672	95,534	23,978
Interest paid	3,251	2,450	13,263
Interest received	212	135	1,460
Income tax paid	3,386	1,889	10,910

Changes in Consolidated Equity

as at 31 March 2012

	Parent company						Minority interests	Consolidated equity Total
	Share capital EUR '000	Treasury shares EUR '000	Currency conversion EUR '000	Cashflow Hedges EUR '000	Other reserves EUR '000	Total EUR '000	EUR '000	EUR '000
Balance as at 31.12.2010	53,219	-14,384	-8,403	0	152,136	182,568	332	182,900
Group net income	0	0	0	0	9,159	9,159	112	9,271
Other results								
Cashflow Hedges	0	0	0	-4,425	0	-4,425	0	-4,425
Currency conversion differences	0	0	-2,169	0	0	-2,169	0	-2,169
Total result of the period	0	0	-2,169	-4,425	9,159	2,565	112	2,677
Transactions with shareholders								
Dividend distribution	0	0	0	0	-12,557	-12,557	0	-12,557
Stock option program	0	0	0	0	41	41	0	41
Additional share purchase from minority interests after control	0	0	0	0	-2,613	-2,613	-374	-2,987
Purchase of own shares	0	-1,873	0	0	0	-1,873	0	-1,873
	0	-1,873	0	0	-15,129	-17,002	-374	-17,376
Balance as at 31.12.2011	53,219	-16,257	-10,572	-4,425	146,166	168,131	71	168,202
Group net income	0	0	0	0	8,052	8,052	0	8,052
Other results								
Cashflow Hedges	0	0	0	-1,304	0	-1,304	0	-1,304
Currency conversion differences	0	0	782	0	0	782	0	782
Total result of the period	0	0	782	-1,304	8,052	7,530	0	7,530
Transactions with shareholders								
Dividend distribution	0	0	0	0	0	0	0	0
Stock option program	0	0	0	0	5	5	0	5
Additional purchase of shares from minority interests after control	0	0	0	0	0	0	0	0
Purchase of own shares	0	-901	0	0	0	-901	0	-901
	0	-901	0	0	5	-896	0	-896
Balance as at 31.03.2012	53,219	-17,158	-9,790	-5,729	154,223	174,765	71	174,836

Explanatory notes

THE COMPANY

CompuGroup Medical AG (parent company) is a company registered in Germany in the commercial register of the local court of Koblenz under HRB No. 4358. The Company's registered office is at Maria Trost 21, Koblenz. The object and primary activities of the Company can be characterized as follows:

The Group is currently divided into three business areas, Health Provider Services I (HPS I) and Health Provider Services II (HPS II) as well as Health Connectivity Services (HCS). These areas form the basis for the Company's segment reporting. In departure from prior year the management of CompuGroup decided to reorganize the segmentation with the conclusion that the business area Consumer Health Services (CHS) is no longer relevant for the strategic focus of the segmentation. For 2012 the business area Health Provider Service (HPS) is split by product and clients for office-based doctors, dentists and pharmacists (HPS I) and hospitals (HPS II). Products and clients for office-based doctors and pharmacists have been grouped together under a common HPS I segment as these businesses share many of the same operating and financial characteristics. The previous years' figures were adjusted accordingly.

HPS I: Development and marketing of software solutions for office-based doctors, dentists and pharmacists

HPS II: Development and marketing of software for hospitals

HCS: Networking of healthcare service providers (doctors, dentists, hospitals and pharmacists) with other key market participants such as medical insurance companies, pharmaceutical companies and others

The Company's shares are traded in the official market segments of the Frankfurt Stock Exchange since 4 May 2007.

General Accounting Principles for the Interim Financial Report

General Accounting Principles

This condensed IFRS-Interim Financial Report for the period ended 31 March 2012 is a consolidated financial statement. Unless otherwise specified, all amounts are provided in thousands of euros (EUR thousands) or millions of euros (EUR millions). Rounding differences of +/- one unit (EUR thousands, percent, etc.) may arise as a result of calculations.

This three month financial statement has been prepared in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standard Board (IASB) as adopted by the EU. Furthermore, this report has also been prepared in accordance with IAS 34 "Interim Financial Reporting".

The consolidated income statement and the statement of financial positions comply with the subdivision presentation rules IAS 1 "Presentation of Financial Statements", whereby the income statement has been prepared under the total expense format.

Unless stated otherwise, all figures refer to the three month of 2012 and 2011 respectively.
This condensed three month financial report does not contain all information and explanatory notes that would be required for consolidated annual financial statements and should be viewed in conjunction with the audited consolidated financial statements for the year ended 31 December 2011, which may be obtained from the Company's website www.cgm.com.

Generally, this financial report is based on the historical cost principle. As far as nothing else is noted, all assets and liabilities are carried at historical acquisition or production cost, less required depreciation, amortization and impairment. The underlying estimates and assumptions used in the preparation of this IFRS three month financial report have an impact on the measurement of assets (e.g. goodwill, deferred tax assets) and liabilities (e.g. provisions, purchase price liabilities), contingent assets and liabilities shown at respective statement of financial position dates, and the amount of income and expense for the reporting period. Although these assumptions and estimates were made to the best knowledge of the Management Board, actual results may differ from these estimates.

The Management Board believes that this report contains all the information and adjustments necessary to present a true and fair view of the net assets, financial position and earnings of the Company. These results for the current fiscal year do not necessarily allow conclusions to be drawn with regard to future business.

The Company's business is not subject to significant business cycle or seasonal fluctuations.

In preparing this condensed IFRS-Interim Financial Report, the same accounting policies have been applied as for the previous consolidated financial statements as at 31 December 2011 with the exception of the following listed new IFRS-Standards and Interpretations.

Changes that apply from 1 July 2011
IFRS 1 – Severe Hyperinflation and Removal of Fixed Dates for First-Time Adopters
IFRS 7 – Financial Instruments: Disclosures

Changes that apply from 1 January 2012
IAS 12 – Deferred tax: Recovery of Underlying Assets

Changes that apply from 1 July 2012
IAS 1 – Presentation of Items of Other Comprehensive Income

Changes and new standards that apply from 1 January 2013
IAS 19 – Employee Benefits
IAS 27 – Separate Financial Statements
IAS 28 – Investments in Associates and Joint Ventures
IFRS 10 – Consolidated Financial Statements
IFRS 11– Joint Arrangements
IFRS 12 – Disclosures of Interests in Other Entities
IFRS 13 – Fair Value Measurement
IFRIC 20 – Stripping Costs in the Production phase of a Surface Mine

Changes that apply from 1 January 2014
IAS 32 – Financial Instruments: Presentation: Classification of Right

Changes and new standards that apply from 1 January 2015
IFRS 9 – Financial Instruments

In general, the first-time mandatory application of new and changed IAS/IFRS could lead to changes within the currently applied accounting policies. It is expected that the change of IFRS 7 is having an impact on the consolidated financial statements of 2012. Impacts on the consolidated financial statements which may will arise from change in IAS 19, IAS 27, IAS 28, IFRS 10, IFRS 11, IFRS 12, IFRS 13 and IFRIC 20 (all effective from 1 January) are expected, but cannot be entirely estimated at the present point of time.

The impacts on the consolidated financial statements arising from the changes of IAS 32 (effective from 1 January 2014) and from the first-time application of IFRS 9 (effective from 1 January 2015) are currently not foreseeable.

This condensed IFRS-Interim Financial report for the period ended 31 March 2012 was not submitted to an audit according to §317 German Commercial Code (HGB) as well as not reviewed by the auditors.

Consolidation Principles
The same consolidation principles have been applied as in the previous consolidated financial statements for the year ended 31 December 2011, which contain a detailed explanation of these principles.

Reporting Entity Structure
The three month financial report includes the financial statements of the Company and companies under its control (its subsidiaries) as at 31 March 2012.

All of CompuGroups' consolidated financial statements are prepared according to consistent accounting policies. Shares in associated companies substantially controlled by the Company exercises significant influence (with voting rights of between 20 percent and 50 percent) are accounted by using the equity method.

The following significant changes have taken place with regard to the reporting entity structure compared to the previous year:

+ Acquisition of Microbais Werkmaatschappij B.V. (Netherlands): Effective 1 January 2012 CompuGroup acquired 100 percent of the shares of Microbais Werkmaatschappij B.V. Microbais is one of the leading companies in the Dutch market which provides Ambulatory and Pharmacies Information Systems. The purchase price amounts to approximately EUR 15.0 million. In 2011 revenue was at approximately EUR 11.2 million and an EBITDA of EUR 2.5 million. The company has approximately 90 employees and is located in Amsterdam. With its customers of 475 pharmacies and 150 doctor's practices Microbais has a market share of 25 percent respectively 4 percent.

+ Acquisition of Effepieffe srl (Italy): In January 2012 CompuGroup signed a contract to purchase 100 percent of the shares of Effepieffe srl by its subsidiary CompuGroup Medical Italia S.p.A. In 2011 the revenue was at approximately EUR 1.2 million and the EBITDA at approximately EUR 0.5 million. CompuGroup paid a purchase price of EUR 3.4 million for number three in the Italian market for Ambulatory Information Systems. Under certain conditions the purchase price raises at EUR 1.0 million. The company counts approximately 8,000 general practitioners among its customers.

Consolidation of Capital, Liabilities and Income
Please refer to the consolidated financial statements for the year ended 31 December 2011.

Foreign Currency Conversion
Functional currency is the respective national currency used in the local economic environment. The reporting currency is the EURO which is the functional currency of the parent company. For further information on currency conversion please refer to the consolidated financial statements for the year ended 31 December 2011.

Corporate Governance Code
In accordance with § 161 of the German Stock Corporation Act (AktG), the prescribed declaration of compliance has been submitted by the Management Board and the Supervisory Board and is available to shareholders on the Company's website www.cgm.com.

EXPLANATIONS TO THE BALANCE SHEET AND PROFIT AND LOSS ACCOUNT

1. Intangible assets
As at 31 March 2012 intangible assets accounted for EUR 467.5 million. This corresponds to an increase of EUR 8.8 million compared to 31 December 2011. The increase mainly pertained to the acquisition of Microbais and Effepieffe.
During the first three months, the amortization of intangible assets amounted to EUR 7.4 million, primarily attributable to acquired software, brands and customer relations from acquisitions.

2. Tangible assets
As at 31 March 2012 tangible assets accounted for EUR 59.1 million. This corresponds to an increase of EUR 8.9 million compared to 31 December 2011. The increase mainly pertained to the continued construction of the new administration building at the company headquarter in Koblenz (EUR 2.5 million). The new building was completed and inaugurated in April 2012. Also, the building 'Maria Trost 21' in Koblenz, which has been rented and used by CompuGroup for more than 10 years, was purchased during the quarter for EUR 6.1 million.

3. Trade receivables
As at 31 March 2012 trade receivables increased at EUR 6.0 million to EUR 75.7 million. This increase mainly results from invoices across the quarters and invoices in the new companies acquired. The related deferred income is disclosed in the other non-financial liabilities.

4. Company capital
Share capital
As at 31 March 2012 the share capital of the company amounts to EUR 53,219,350, divided into 53,219,350 no-par-value bearer shares with a value of EUR 1.00 per share.

Authorized capital
By resolution of the General Meeting dated 16 August 2006, the Management Board is authorized until 16 August 2011, with the approval of the Supervisory Board, to increase the share capital up to EUR 22,939,375 by issuing new shares on one or more occasions against cash and/or in kind distributions. The commercial register entry took place 28 September 2006. During the IPO on 4 May 2007 the share capital was increased by EUR 7,340,600 from the authorized capital.

Treasury shares
By resolution of the General Meeting dated 19 May 2010, the Management Board was authorized to acquire its own shares until 19 May 2015. In accordance with Section 71 paragraph 1 No. 8 German Stock Corporation Act (AktG), the Company is authorized to acquire or hold its own shares, up to a total of 10 percent of the current share capital.

Financial year	Period of buy back program	Amount of treasury shares	Purchase price per share in bands from	Average weighted purchase price
2007		532,350		
2008	23 January to 18 April 2008	500,000	EUR 8.6430 to 12.6788	EUR 10.3276
2008	22 July to 14 October 2008	500,000	EUR 3.8243 to 5.4881	EUR 4.8426
2008	15 October to 30 December 2008	428,736	EUR 3.1519 to 4.4279	EUR 3.8849
2009	5 January to 31 March 2009	403,876	EUR 3.4100 to 4.7402	EUR 4.0810
2009	1 April to 27 May 2009	500,000	EUR 3.8357 to 4.5988	EUR 4.1578
2009	4 June to 31 December 2009	125,746	EUR 4.1853 to 6.0000	EUR 5.6852
2010	No acquisitions			
2011	17 August to 31 December 2011	225,553	EUR 7.6496 to 9.3140	EUR 8.3033
2012	2 January to 30 June 2012	101,835	EUR 8.4394 to 9.9764	EUR 8.8488
Total		3,318,096		

Reserves
The company's reserves relate exclusively to retained earnings, foreign currency translation differences and share premiums from the initial public offer in 2007 (EUR 127.9 million). As at 31 March 2012 the reserves amount to EUR 138.7 million compared to EUR 131.2 million as at 31 December 2011. The increase mainly derives from the allocation of the profit.

5. Liabilities to banks
As at 31 March 2012 the total debt to credit institutions amount to EUR 262.8 million compared to EUR 269.7 million as at 31 December 2011.

In January 2010, two loans were taken out with IKB Deutsche Industriebank, Düsseldorf (IKB No. 3 and IKB No. 4) that were refinanced by the KfW (KfW Bankengruppe or German Development Bank). Each loan has a value of EUR 10.0 million. Both loans were fully utilized as of 31 December 2010. The loan IKB No. 3 has a 3.9 percent fixed interest rate. Interest is payable at the end of each financial quarter. The principle repayment is to be made quarterly in the amount of EUR 625 thousand; the first repayment was due on 30 September 2011. The loan has a term until 30 June 2015. The loan IKB No. 4 has a 4.45 percent interest rate. Interest is payable at the end of each financial quarter. The principle repayment is to be made quarterly in the amount of EUR 833 thousand; the first repayment is due on 30 September 2012. The loan has a term until 30 June 2015.

CompuGroup Medical AG concluded a loan agreement with an execution date of 22 December 2010 for a total sum of EUR 300.0 million. The loan consists of a "term loan facility" (also referred to in the following as "TLF") for EUR 160.0 million and a "multi currency revolving loan facility" (also referred to in the following as "RLF") for EUR 140.0 million, both of which mature on 22 December 2015. A change made on 5 May 2011 increase the TLF amount to EUR 190.0 million; the repayment amounts were adjusted accordingly. The TLF must be repaid in EUR 15.0 million installments twice a year from 31 January 2012, whereas the RLF must be repaid at the end of each interest period and can be taken out again immediately thereafter. CGM selected an interest period of three months. The interest rate is based upon the appropriate EURIBOR rate for the interest period chosen plus a margin derived from the relationship between the consolidated net debt and adjusted EBITDA. As at 31 March 2012, EUR 175.0 million of the TLF and EUR 62.0 million of the RLF were utilized. Transaction costs totalling EUR 6.5 million were incurred related to these facilities. These fees will be charged as an expense over the term of the loan agreement. The grant of the loan is linked to meeting certain financial key figures. The loan agreement with SEB AG includes joint and several guarantees for payment by a number of Group subsidiaries (contingent liability in case of non-payment of CompuGroup Medical AG).

In the first quarter 2012 CompuGroup concluded a further loan agreement of EUR 6.1 million to finance the purchase of the office building 'Maria Trost 21'. The conditions in this loan agreement are a 10 year secured real-estate mortgage loan with a fixed interest rate of 3.3 percent.

6. Other non-financial liabilities
Other non-financial liabilities increased by EUR 47.8 million to EUR 76.7 million during the first three months of 2012. This pertains mainly to the increase of pre-payments of maintenance contracts (EUR 45.9 million) and VAT liabilities (EUR 2.1 million).

7. Capitalized in-house services

Capitalized in-house services relates exclusively to the activation of self-developed software. During the first three months of 2012 a total of 39,508 working hours (EUR 1.5 million) were classified for activation. In the same period in 2011, 46,484 hours (EUR 1.7 million) were activated. The country specific hourly range is in 2012 between approx. EUR 15 and approx. EUR 45 per hour. During the first three month the depreciation on the already finished software amounted to 0.8 EUR million (first three months of 2011: EUR 0.7 million).

8. Special effects on the profit and loss account

Please see comments in the interim management report.

9. Hedging activity

Derivative financial instruments hedge against the effects of interest rate fluctuations. Variable interest rates were fixed with terms and a multicurrency revolving loan facility using interest rate swaps. Interest rate swaps (hedging transactions) were designated in a cash flow hedge with the term and multicurrency revolving loan facility (hedged item). The ineffective portion of cash flow hedges amounts to EUR 0.

The nominal amount of interest rate swaps in hedge accounting amounted to EUR 250.0 million as of 31 March 2012 (31 December 2011: EUR 250.0 million). As at 31 March 2012, the fixed interest rates ranged from 1.83 percent to 2.07 percent; the variable interest rate was the 3 month EURIBOR.

Profits and losses from interest rate swaps accounted in the equity hedge reserve as at 31 March 2012 of EUR -1.3 million (31 December 2011: EUR -4.4 million) contain interest rate hedging instruments measurements.

10. Group rate of taxation transition

The group tax charge consists of the current tax charge and deferred tax. The current tax charge is based on the taxable income for the period. The current tax liability is based on the applicable tax rates. Deferred tax represents expected future tax savings or additional charges arising from the difference between book values of assets and liabilities and the values adopted in the taxable income computation. The liability method is used in the deferred tax calculation

EUR ´000 / %	
11,008	EBT - Pre-tax profits
2,956	Taxes on income and earnings from the income statement
26.85%	Effective tax rate for the group
-1.00%	Tax free loss Tepe
3.60%	Tax differences foreign subsidiaries
0.20%	Other differences
29.65%	Theoretical tax rate for the group

11. Employees

CompuGroup had an average of 3,512 employees in the first three months of 2012 (previous year: 3,228).

12. Segment reporting

In this report, CompuGroup follows the application of the new IFRS 8 for the segment reporting. The management of CompuGroup decided to reorganize the segmentation with the conclusion that the business area Consumer Health Services (CHS) is no longer relevant for the strategic focus of the segmentation. For 2012 the business area Health Provider Service (HPS) is split by product and clients for office-based doctors, dentists and pharmacists (HPS I) and hospitals (HPS II). Products and clients for office-based doctors and pharmacists have been grouped together under a common HPS I segment as these businesses share many of the same operating and financial characteristics. The previous years' figures were adjusted accordingly. All transactions between the segments are calculated at fair market values.

	Segment I: Health Provider Services I (HPS I)			Segment II: Health Provider Services II (HPS II)			Segment III: Health Connectivity Services (HCS)		
EUR ´000	2012 Jan-Mar	2011 Jan-Mar	2011 Jan-Dec	2012 Jan-Mar	2011 Jan-Mar	2011 Jan-Dec	2012 Jan-Mar	2011 Jan-Mar	2011 Jan-Dec
Sales to third parties	75,562	56,244	254,025	18,784	17,621	76,217	17,643	16,321	65,628
Sales between segments	375	375	3,430	1,562	2,715	9,295	46	39	2,009
SEGMENT SALES 1)	75,937	56,619	257,455	20,346	20,336	85,512	17,689	16,360	67,637
EBITDA	22,066	13,628	65,674	2,377	1,932	8,472	5,762	4,018	22,472
in % of sales	29.2	24.2	25.9	12.7	11.0	11.1	-	-	-
Depreciation on tangible assets	-1,123	-746	-2,811	-413	-428	-1,879	-82	-69	-259
Amortization on intangible assets	-4,772	-5,211	-20,608	-1,917	-1,943	-7,370	-607	-665	-1,469
Impairment for financial assets	0	0	0	0	0	0	0	0	0
EBIT	16,171	7,671	42,255	47	-439	-777	5,073	3,284	20,744
Earnings of associated companies	11	-	22	-	-	-	-	-	-
Interest income	-	-	-	-	-	-	-	-	-
Interest expenses	-	-	-	-	-	-	-	-	-
EBT	-	-	-	-	-	-	-	-	-
Corporation tax	-	-	-	-	-	-	-	-	-
GROUP NET INCOME	-	-	-	-	-	-	-	-	-
in % of sales	-	-	-	-	-	-	-	-	-
GROUP NET INCOME before amortization on intagible assets	-	-	-	-	-	-	-	-	-

1) Total Sales (excluding changes in inventory, capitalized in-house services and other operating income)

All other Segments 2012 Jan-Mar	All other Segments 2011 Jan-Mar	All other Segments 2011 Jan-Dec	Consolidation adjustments 2012 Jan-Mar	Consolidation adjustments 2011 Jan-Mar	Consolidation adjustments 2011 Jan-Dec	CompuGroup Group 2012 Jan-Mar	CompuGroup Group 2011 Jan-Mar	CompuGroup Group 2011 Jan-Dec
255	87	694	0	0	0	112,244	90,273	396,564
4,020	2,532	10,893	-6,003	-5,661	-25,627	0	0	0
4,275	2,619	11,587	-6,003	-5,661	-25,627	112,244	90,273	396,564
-3,893	-5,604	-23,553	0	0	0	26,312	13,974	73,065
-	-	-	-	-	-	23.4	15.5	18.4
-278	-238	-1,368	0	0	0	-1,896	-1,481	-6,317
-151	-43	-646	0	0	0	-7,447	-7,862	-30,093
0	0	0	0	0	0	0	0	0
-4,322	-5,885	-25,567	0	0	0	16,969	4,631	36,655
-	-	-	-	-	-	11	0	22
-	-	-	-	-	-	398	680	4,826
-	-	-	-	-	-	-6,370	-3,579	-16,305
-	-	-	-	-	-	11,008	1,732	25,198
-	-	-	-	-	-	-2,956	-707	-15,927
-	-	-	-	-	-	8,052	1,025	9,271
-	-	-	-	-	-	7.2	1.1	2.3
-	-	-	-	-	-	15,499	8,887	39,364

13. Other financial obligations and financial commitments

Other financial obligations and financial commitments as at 31 March 2012 consist of the following:

EUR '000	01.01-31.03 2012	01.01-31.03 2011
One year or less	10,966	6,161
Between two and five years	13,834	8,680
Longer than five years	10,025	3,814
	34,824	18,655

Payments from operating lease relationships involve rent for the Group's office equipment and particularly for office buildings (without purchase option). Leasing relationships are concluded for an average term of three years. The rents are fixed for three to seven years. Operating leasing relationships are shown in the balance sheet with a pro rata effect on income.

There are no larger purchase commitments from operations. As part of a project contract concluded in November 2008 with the Vienna Hospital Group (KAV), Systema Human Information Systems GmbH gave a performance guarantee for EUR 3.6 million to KAV. Furthermore, the Company has deposited EUR 23 thousand with the landlord for the rental of office space and a computer center in St. Pölten.

CompuGroup Medical Österreich GmbH has deposited over EUR 8 thousand with the landlord for the rental of office space in the premises in Hall.

Systema Deutschland GmbH gave a performance guarantee in relation to a customer transaction of EUR 44 thousand.

CompuGroup Medical AG has assumed a guarantee in favor of Meteksan Sistem ve Bilgisayar Teknolojileri A.S. for YTL 210 thousand (EUR 98 thousand) for Tepe Teknolojik Servisler A.S.

In the course of its business "Tepe International A.S" participates in foreign and domestic tenders and normally must provide a guarantee in order to participate in the tender. To secure this deposit CompuGroup Medical AG has guaranteed USD 5.0 million at Fortis Bank (Turkey).

Under the terms of the joint venture agreement of 15 November 2004 between United Pascal Holdings B.V. and CompuGROUP Beteiligungsgesellschaft to found UCF Holding S.a.r.l. Luxembourg, CompuGroup Medical AG as the parent company is obliged to guarantee the liquidity of CompuGROUP Beteiligungsgesellschaft. The reason for this is that United Pascal Holdings B.V. has, at term, the right to sell its minority stake. As at 31 March 2012, this purchase obligation would have been valued at around EUR 5.4 million if the put right had been exercised.

The Company has taken over a guarantee for EUR 6.9 million in favor of the landlords Friedrich and Jan Christopher GmbH and Geschwister Christoffer GbR on behalf of the associate company Medistar Praxiscomputer GmbH as part of an existing rental agreement.

The Company has given a surety of EUR 15 thousand to Gesmo Gesellschaft für Mobilfunkservices mbH, Marburg at Commerzbank.

The Company has taken over a guarantee of EUR 350 thousand in favor of BECOM Electronics GmbH for Gesellschaft KoCo Connector AG.

In accordance with the guarantee bond dated 29 August 2011, the Company has given a credit guarantee limited to USD 2,500,000 to Bank of America for CompuGroup Holding US Inc.

The American subsidiary CompuGroup Medical Inc. has deposited a rent guarantee in the amount of EUR 24 thousand for the landlord at Idaho Central Credit Union as well as a rent guarantee of EUR 144 thousand for KPL Landerhaven, LLC.

The sellers have an irrevocable put option for the acquisition of the remaining shares (24.5 percent) of CompuGroup Medical Sweden AB in Profdoc LAB, AB in the year 2013 at a purchase price of SEK 22.05 million (equivalent to EUR 2.49 million as of 31 March 2012). CompuGroup Medical AG has guaranteed the payment as per the credit guarantee dated 22 September 2009.

The Turkish subsidiary Tepe International A.S has issued guarantees of EUR 441 thousand for customer orders.

The Turkish subsidiary CompuGroup Medical Bilgi Sistemleri A.S. has issued guarantees of EUR 311 thousand for customer orders.

An interest and principle guarantee has been entered into in favor of Landesbank Saar Girozentrale on behalf of the associated company IMMO I GbR (in the course of the purchase of additional shares and subsequent merger with CompuGROUP Beteiligungsgesellschaft mbH) with relation to financing by Landesbank Saar Girozentrale. CompuGroup Medical AG undertakes to ensure that the debtor assumes all present and future interest and principle payments on time or else will make such payments for them.

This refers to two loans with the following conditions:

Original credit amount (EUR)	Interest rate (%)	Monthly repayment (EUR)	Fixed interest period
1,121,000	5.5%	12,144	30.12.2012
1,879,000	5.5%	0	30.12.2012
3,000,000		12,144	

Only interest will be paid for the loan for EUR 1,879 thousand until 30 December 2012.

The loans were valued at EUR 2.0 million as at 31 March 2012.

As part of the interest rate adjustment on 30 December 2012 a repayment agreement has to be made within 10 years so that the total term of 20 years is not exceeded.

14. Company acquisitions

Date of purchase	Ascon 01.01.2011 EUR '000	Healthport 01.01.2011 EUR '000	Lorensberg 01.01.2011 EUR '000
1) Assets			
I. Non current assets	2,261	687	168
II.Current assets cash and cash equivalents	1,078	254	1,454
III.Current assets without cash and cash equivalents	2,975	2,546	1,628
2) Liabilities and shareholder's equity			
I. Long-term borrowed capital	2,235	149	0
II.Short-term borrowed capital	3,052	3,377	1,271
3) Acquisition of shareholder's equity	1,026	-39	1,980
External portion			
Purchase price allocation			
Goodwill, software	2,798	3,603	550
Goodwill, business value	3,144	4,666	707
Goodwill, customer relationship	11,563	6,668	1,301
Goodwill, brand	1,215	0	727
Goodwill, backlog	0	0	0
Goodwill, building	0	0	0
Advance payment of purchase price (prior year)	-15,000	0	0
Gain resulting of fair value evaluation	0	0	0
Purchase price liability	-1,100	0	0
Deferred tax assets on loss carried forward			
Deferred tax liabilities on goodwill	-3,646	-1,512	-782
Paid purchase price as at 31 March 2012	0	13,386	4,483
Total purchase cost	1,100	13,386	4,483
According to allocation	0	13,386	4,483
4) Percentage of voting rights acquired (%)	100	100	100
5) Acquired funds	1,078	254	1,454
6) Result following initial consolidation	n.a.	n.a.	n.a.
7) Result under the premise that no takeover had taken place under the period 1 January-31 March 2012	n.a.	n.a.	n.a.
Step up depreciation	n.a.	n.a.	n.a.
8) Sales revenues since initial consolidation	n.a.	n.a.	n.a.
9) Sales revenues under the premise that no takeover had taken place under the period 1 January-31 March 2012	n.a.	n.a.	n.a.

The purchase price allocations Lauer-Fischer, Microbais and Effepieffe are provisional.
For proforma data in respect of Ascon, Healthport, Lorensbergs and Parametrix we refer to the Annual Report 2011.

Parametix 01.01.2011 EUR '000	Lauer Fischer 30.06.2011 EUR '000	Microbais 01.01.2012 EUR '000	Effepieffe 01.01.2012 EUR '000	Total 31.03.2012 EUR '000
160	3,320	1,646	407	2,053
0	813	4,667	427	5,094
879	20,501	2,125	146	2,271
0	4,522	11	106	117
1,696	5,805	1,681	536	2,217
-655	14,308	6,747	338	7,085
				0
1,614	10,153	2,140	217	2,357
1,090	30,751	1,883	2,525	4,408
1,611	15,883	5,409	1,910	7,319
309	3,555	945	114	1,059
998	6,763	0	0	0
0	1,000	0	0	0
0	0	0	0	0
0	0	0	0	0
0	-18,838	0	0	0
				0
-67	-11,075	-2,124	-704	-2,828
4,900	52,500	15,000	4,400	19,400
4,900	71,338	15,000	4,400	19,400
4,900	52,500	15,000	4,400	19,400
100	75	100	100	
0	813	4,667	427	5,094
n.a.	n.a.	277	-10	267
n.a.	n.a.	277	-10	267
n.a.	n.a.	117	32	149
n.a.	n.a.	2,847	279	3,126
n.a.	n.a.	2,847	279	3,126

Additional Information

FINANCIAL CALENDAR 2012

Date	Event
4 May 2012	First quarter 2012 report
9 May 2012	Annual General Meeting, Koblenz
9 August 2012	Second quarter 2012 report
14 November 2012	Third quarter 2012 report

SHARE INFORMATION

The CompuGroup share finished the third quarter with a closing price of EUR 10.60. The average closing share price increased by 13 percent from EUR 8.64 (Q4/2011) to EUR 9.74 (Q1/2012).

The highest quoted price during the quarter was EUR 11.45 on 13 March 2012 and the lowest price EUR 8.15 on 31 January 2012.

The trading volume of CompuGroup shares was 1.4 million shares during the first quarter, up 24 percent compared to the previous quarter. On average, the daily trading volume was 21,233 shares.

By the end of March 2012, a total of five analyst companies were covering the CompuGroup Medical share on a regular basis. The forecast price targets ranged from EUR 11.00 to EUR 14.00. Four analysts rated the shares a "buy" and one analyst as "overweight".

CONTACT INFORMATION

CompuGroup Medical AG
Investor Relations
Maria Trost 21
56070 Koblenz
Germany

T. +49 (0) 261 8000-6200
F. +49 (0) 261 8000-3200
investor@cgm.com

www.cgm.com

Management Responsibility Statement

To the best of our knowledge, and in accordance with applicable accounting principles for interim financial reporting, the consolidated interim financial statements give a true and fair view of the net assets, financial position and results of operations of the Group, and the Group interim management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group over the remainder of the financial year.

Koblenz, 4 May 2012

CompuGroup Medical Aktiengesellschaft
The Management Board

Frank Gotthardt | Christian B. Teig | Uwe Eibich

CompuGroup Medical AG
Maria Trost 21
56070 Koblenz
Germany

www.cgm.com